Proactive Investors - Run By Investors For Investors

VolitionRx's Nu.Q blood-based diagnostic tests offer great potential, says Oppenheimer analyst

Analyst Mark Breidenbach's valuation is based primarily on Nu.Q's market opportunity for colorectal cancer screening in the US and EU
Cancer cells
VolitionRx develops and markets its cost-effective Nu.Q blood-based tests to accurately diagnose colorectal cancer

The easy-to-use Nu.Q blood-based diagnostics tests offered by VolitionRx Ltd (NYSEAMERICAN:VNRX) will provide a key tool in screening for colorectal cancer going forward, says Mark Breidenbach, an analyst with Oppenheimer.

In a note to investors, Breidenbach argues that the Belgium-based company’s diagnostic tests for different cancers can “meaningfully improve the gap in screening compliance for colorectal cancer.”

“We see the company’s products for colorectal cancer screening as its primary value drivers,” he added.

Breidenbach’s valuation of VolitionRx is based primarily on Nu.Q’s market opportunity for colorectal cancer screening in the US and European Union.

Currently, VolitionRx develops and markets its cost-effective Nu.Q blood-based tests to accurately diagnose colorectal cancer as well as a broad range of other cancers. The tests are based on VolitionRx’s Nucleosomics technology platform, which identifies and measures nucleosomes in the bloodstream or in other bodily fluid.

On Monday, VolitionRx revealed that it expects modest initial revenue starting in the coming quarter due to the sale of its Nu.Q blood-based tests.

Read: VolitionRx expects its Nu.Q blood-based test kits to generate new revenue in coming quarter

Among the Belgium-based company’s recent wins announced along with second-quarter results is a sales agreement with Active Motif for an array of Research-Use-Only kits, the first of which, the Nu.Q Total assay kit is now on the market.

“We expect modest initial revenue in the coming quarter, building through next year and beyond,” the company said in a statement.

Additional advances announced at the end of the second quarter include VolitionRx’s move to sign agreements to conduct two colorectal cancer research studies across Asia in collaboration with the National Taiwan University.

The company also released preliminary data from a study that showed its Nu.Q assay kits diagnosed men with aggressive prostate cancer with 94% accuracy, which prompted praise from Breidenbach.

Read: VolitionRx unveils data showing its Nu.Q assays detect aggressive prostate cancer in men with 94% accuracy

“While we caution against making broad conclusions from small pilot studies, we believe these data highlight the potential of VolitionRx’s tech platform in applications well beyond colorectal cancer,” Breidenbach wrote.

VolitionRx ended the second quarter with US$11.9mln in cash, which combined with its recent US$9mln private placement, could sustain its business operations until the middle of next year, Breidenbach added.

The analyst reiterated his Outperform rating on VolitionRx, but adjusted his price target to US$6 from US$7 to reflect delays in clinical trials involving the Nu.Q tests.

Contact Ellen Kelleher at [email protected]


View full VNRX profile View Profile

VolitionRx Timeline

Related Articles

February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
woman's face
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use